Trial Equity and MTA Join Forces to Boost Clinical Trial Diversity

Medical researchPhoto by Karolina Grabowska on Pexels.com

PHILADELPHIA, PA — Trial Equity has partnered with Miller Tanner Associates (MTA) in a bid to enhance education and participation among diverse patient groups in clinical trials. This collaboration targets pharmaceutical sponsors, contract research organizations (CROs), and site networks, aiming to address the critical gap in clinical trial diversity.

MTA, a Women’s Business Enterprise National Council-certified leader in life sciences event planning, will co-market Trial Equity’s Clinical Trial Diversity Training. MTA’s expertise in managing Face-to-Face, Virtual, and Hybrid meetings will help promote this training through its Event Content Management platform, VALTs.

Dr. Otis Johnson, Co-founder of Trial Equity, explained the partnership’s strategic importance: “MTA’s deep expertise in life sciences and their innovative VALTs platform are crucial for globally delivering our Clinical Trial Diversity Training. This partnership is a key step toward ensuring medical breakthroughs reflect the diverse communities we serve.”

Trial Equity’s eLearning course and in-person workshops offer a comprehensive curriculum designed to improve representation in clinical trials. These initiatives respond directly to disparities highlighted by the Tufts Center for the Study of Drug Development, which noted the lack of infrastructure for engaging diverse patient populations.

Scott Nodolf, MTA’s Chief Revenue Officer, emphasized the urgency of addressing trial diversity: “Diversity in clinical trials is a significant challenge that demands immediate action. Our partnership with Trial Equity will help transform the industry and meet the evolving needs of our customers.”

Advancing Healthcare: Empowering Diversity in Clinical Trials

This collaboration could have broad implications for the healthcare sector. Enhanced diversity in clinical trials ensures that new medical treatments are effective across varied populations. This is crucial for developing therapies that work well for all segments of society, thereby improving overall public health outcomes.

READ:  New White Paper Shines Light on Critical Issues in Women's Health

For pharmaceutical companies, CROs, and site networks, investing in diversity training can lead to more comprehensive and reliable clinical trial results. This, in turn, can accelerate the approval process for new drugs, ultimately benefiting patients who need them.

MTA’s involvement leverages its logistical prowess and international reach, making it easier for Trial Equity’s training programs to gain traction worldwide. By incorporating these diversity-focused training sessions into Investigator Meetings, MTA will help healthcare professionals implement more inclusive practices.

In conclusion, the partnership between Trial Equity and MTA represents a significant advancement in addressing clinical trial diversity. By combining their strengths, they aim to foster a more inclusive approach to medical research, ensuring that future treatments are effective for everyone.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.